Table 3

Crude and adjusted HRs for anaemia among patients with prostate cancer during a 3-year follow-up period stratified by the duration of ADT

Presence of iron-deficiency anaemiaPatients receiving short-term ADT (n=3631) *Patients receiving long-term ADT (n=3634) *Patients not receiving ADT
(n=3631)
Three-year follow-up period
Incidence rate per 100 person-years (95% CI)2.24 (1.87 to 2.62)1.25 (1.02 to 1.48)1.01 (0.78 to 1.25)
Crude HR (95% CI)2.19 (1.64 to 2.92)1.25 (0.93 to 1.69)1.00
Adjusted HR (95% CI)†‡2.20 (1.64 to 2.94)1.22 (0.90 to 1.65)1.00
Adjusted HR (95% CI)†§2.06 (1.53 to 2.76)1.23 (0.91 to 1.66)1.00
  • *We categorised the patients receiving ADT into two levels according to the median duration of ADT use (144 days).

  • †Using a Cox proportional regression with data censored if individuals died during the 3-year follow-up period;.

  • ‡Adjustments were made for patients’ geographic location, monthly income, urbanisation level, age and incidence of hyperlipidaemia, diabetes, hypertension, coronary heart disease and inflammatory bowel disease.

  • §Adjustments were made for patients’ geographic location, monthly income, urbanisation level, age and incidence of hyperlipidaemia, diabetes, hypertension, coronary heart disease, inflammatory bowel disease, other cancers and gastrointestinal bleeding.

  • ADT, androgen deprivation therapy.